Skurnik Mikael
Department of Bacteriology and Immunology, Medicum, Human Microbiome Research Program, Faculty of Medicine, University of Helsinki, 00290 Helsinki, Finland.
Division of Clinical Microbiology, HUSLAB, University of Helsinki and Helsinki University Hospital, 00290 Helsinki, Finland.
Antibiotics (Basel). 2022 Apr 26;11(5):575. doi: 10.3390/antibiotics11050575.
Increasing antibiotic resistance numbers force both scientists and politicians to tackle the problem, and preferably without any delay. The application of bacteriophages as precision therapy to treat bacterial infections, phage therapy, has received increasing attention during the last two decades. While it looks like phage therapy is here to stay, there is still a lot to do. Medicine regulatory authorities are working to deliver clear instructions to carry out phage therapy. Physicians need to get more practical experience on treatments with phages. In this opinion article I try to place phage therapy in the context of the health care system and state that the use phages for precision treatments will require a seamless chain of events from the patient to the phage therapy laboratory to allow for the immediate application of phages therapeutically. It is not likely that phages will replace antibiotics, however, they will be valuable in the treatment of infections caused by multidrug resistant bacteria. Antibiotics will nevertheless remain the main treatment for a majority of infections.
不断增加的抗生素耐药菌数量迫使科学家和政治家都要解决这个问题,而且最好不要有任何拖延。在过去二十年里,将噬菌体作为精准疗法来治疗细菌感染,即噬菌体疗法,受到了越来越多的关注。虽然看起来噬菌体疗法会持续存在,但仍有很多工作要做。药品监管机构正在努力提供开展噬菌体疗法的明确指导。医生需要在噬菌体治疗方面获得更多实践经验。在这篇观点文章中,我试图将噬菌体疗法置于医疗保健系统的背景下,并指出将噬菌体用于精准治疗需要从患者到噬菌体治疗实验室的一系列无缝衔接的流程,以便能够立即将噬菌体用于治疗。噬菌体不太可能取代抗生素,然而,它们在治疗由多重耐药菌引起的感染方面将很有价值。不过,抗生素仍将是大多数感染的主要治疗手段。